You are here: Home / GW Innovations / Technologies Available

Stem Cell Therapy for Obesity and Type 2 Diabetes

Technology #016-050-sen

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Glucose tolerance test in obese diabetic mice, 28 days after SOD2 upregulated human MSC delivery, intra-peritoneally.
Sabyasachi Sen
Managed By
Brian Coblitz
Sr. Licensing Associate (202) 994-4345
Patent Protection

Provisional Patent Application Filed
Genetic modification of human mesenchymal stem cells helps to reduce adiposity and improve glucose tolerance in an obese diabetic mouse model
Stem Cell Research and Therapy, 2015; 6: 242.
Files and Attachments
Glucose tolerance test in obese diabetic mice, 28 days after SOD2 upregulated human MSC delivery, intra-peritoneally. [PNG]

Patients with type 2 diabetes have high blood sugar levels due to inadequate insulin production. This could be coupled with insulin resistance and inflammation. High blood sugar levels over a long term can lead to blindness, kidney failure, heart disease and nerve disease which commonly lead to amputations. Overweight and obese people have a much higher risk of developing type 2 diabetes compared to those with a healthy body weight.

One component of the chronic impact from both diabetes and obesity is an increase in reactive oxygen species (ROS) leading to chronic oxidative stress. Usually, antioxidant enzymes called superoxide dismutase (SOD) work to decrease ROS inside a cell which may be lacking in a chronic high glucose state of diabetes and obesity.

Our treatment increases anti-oxidants inside the cell, where they are needed. Our therapy delivers genetically engineered fat-derived mesenchymal stem cells (MSCs) containing increased anti-oxidant enzyme, SOD2, to the inflamed fat depots. Intraperitoneally injected stem cells home in and integrate with the body's fat deposits. This suppresses fat cell -mediated inflammation and improves insulin resistance as evidenced by improved glucose tolerance. The treatment is validated in a diet-induced obesity diabetic mouse model.  SOD2-treated mice had improved glucose tolerance and reduced body weight. 


  • Diabetes  and obesity therapeutics


  • Avoids the multiple co-morbidities of a bariatric surgery.
  • Directly targets insufficiency of antioxidants, intra-cellularly.
  • Reduces inflammation
  • Transforms white fat into brown fat
  • Improves glucose tolerance test
  • Reduces body weight